Pipeline Progress And Global Launches Will Expand Market Reach

Key Takeaways

• Strong product adoption, expanding indications, and pipeline advances support robust, recurring revenue growth and reduce concentration risks.
  
• Alignment with healthcare trends and increasing global disease prevalence drives broader market penetration, supporting long-term revenue and margin expansion.
  
• High dependence on a few key drugs, rising costs, and regulatory or competitive risks threaten growth, margins, and overall financial stability.

Catalysts

Operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.

• Robust adoption and accelerating global launch of YORVIPATH, underpinned by strong demand, broad payer approvals, expanding commercial reach to more countries, and label expansion efforts (e.g., wider indications and higher dosing), is expected to drive sustained top-line revenue growth and support margin leverage as the installed patient base increases and access improves.
  
• Expansion of SKYTROFA into adult growth hormone deficiency and pursuit of further label extensions (pediatric and multiple rare indications), alongside continued dominance in pediatric GHD, broadens the addressable market and enables new recurring revenue streams, contributing to both revenue growth and improving long-term earnings stability.
  
• Regulatory progress and pipeline advancement, such as the priority review for TransCon CNP in achondroplasia and positive combination trial results, are paving the way for new blockbuster therapies and potential multi-billion EUR peak sales opportunities, enhancing future revenue growth and reducing revenue concentration risk.
  
• Long-acting, patient-centric TransCon platform aligns with healthcare provider and payer preferences for convenient, durable treatments, reinforcing strong uptake and value-based reimbursement, thus supporting premium pricing, market penetration, and gross margin improvement.
  
• Increasing global prevalence and diagnosis of chronic endocrine and rare diseases, combined with rising healthcare spending and treatment access in both developed and emerging markets, structurally expands Ascendis's addressable patient pool, facilitating steady, secular demand growth and durable net revenue expansion over the long term.

Ascendis Pharma Future Earnings and Revenue Growth

Assumptions

• Analysts are assuming Ascendis Pharma's revenue will grow by 63.9% annually over the next 3 years.
• Analysts assume that profit margins will increase from -55.3% today to 38.4% in 3 years time.
• Analysts expect earnings to reach €830.8 million (and earnings per share of €12.64) by about August 2028, up from €-271.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting €1.2 billion in earnings, and the most bearish expecting €139.6 million.
• In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 22.0x on those 2028 earnings, up from -36.5x today. This future PE is greater than the current PE for the US Biotechs industry at 14.7x.
• Analysts expect the number of shares outstanding to grow by 5.59% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.45%, as per the Simply Wall St company report.

Ascendis Pharma Future Earnings Per Share Growth

Risks

• Heavy dependence on continued blockbuster growth from YORVIPATH and SKYTROFA-if uptake stalls, reimbursement approval timelines slow, or competitors introduce better or lower-priced alternatives, both revenues and earnings could be substantially impacted in future years.
  
• Elevated SG&A (selling, general, and administrative) costs and global commercial expansion remain high relative to revenues; if quarterly sequential growth moderates or cost discipline weakens, profit margins and cash flow sustainability may be threatened over the long term.
  
• Risks surrounding payer dynamics and drug pricing pressures in the U.S. and international markets: increasing scrutiny, value-based reimbursement, and potential price cuts for rare disease biologics can erode pricing power and compress revenues and net margins.
  
• Reliance on expansion or regulatory successes for future growth (e.g., TransCon CNP label expansion/combo approvals, YORVIPATH higher dose approval in the U.S.)-any delays, failed trials, or unfavorable label outcomes could weaken growth prospects, leading to volatility in future earnings.
  
• Ongoing high R&D investment needs, coupled with increased competition from both established players (such as BioMarin for achondroplasia) and emerging biosimilars, could challenge portfolio differentiation, forcing greater spend to maintain market share and thus impacting both operating margins and net income over time.

Valuation

• The analysts have a consensus price target of $250.081 for Ascendis Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $306.05, and the most bearish reporting a price target of just $201.92.
  
• In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be €2.2 billion, earnings will come to €830.8 million, and it would be trading on a PE ratio of 22.0x, assuming you use a discount rate of 6.4%.
  
• Given the current share price of $191.08, the analyst price target of $250.08 is 23.6% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.